SCHEMBL6522996

SCHEMBL6522996

O=c1[nH]c2ncccc2c2cc(NC3CCN(Cc4ccccc4)CC3)ccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP14 Q460N5 1/20 0.54
ROCK2 O75116 6/20 0.52
ROCK1 Q13464 5/20 0.52
CCR2 P41597 2/20 0.52
ITK Q08881 2/20 0.49
AURKA O14965 1/20 0.47
PARP1 P09874 1/20 0.47
LMNA P02545 1/20 0.46
GBA1 P04062 1/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MALT1 Q9UDY8 1/20 0.45
HRH3 Q9Y5N1 1/20 0.45
SIGMAR1 Q99720 2/20 0.44
ACHE P22303 1/20 0.44
MCHR1 Q99705 1/20 0.44
PDK2 Q15119 1/20 0.44
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6532632 0.81 ROCK2 (0.53) PARP14ROCK2ROCK1CCR2AURKA
SCHEMBL6521588 0.78 NOS2 (0.56) LMNAMAPT
SCHEMBL3319580 0.75 ROCK2 (0.58) PARP14ROCK2ROCK1CCR2ITK
SCHEMBL3454371 0.75 AURKA (0.60) ROCK2ROCK1ITKAURKAPARP1
SCHEMBL5405680 0.74 ROCK2 (0.62) PARP14ROCK2ROCK1CCR2ITK
SCHEMBL7296357 0.73 ROCK2 (0.61) PARP14ROCK2ROCK1CCR2ITK
SCHEMBL11465989 0.72 SIGMAR1 (0.62) ROCK2ROCK1CCR2LMNAGBA1
SCHEMBL6517435 0.72 AURKA (0.67) AURKAPARP1MAPT
SCHEMBL5432812 0.71 ACHE (0.69) ROCK2ROCK1HRH3SIGMAR1ACHE
SCHEMBL3313890 0.71 ROCK2 (0.64) ROCK2ROCK1CCR2ITKLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 PARP14 758/4885ROCK2 736/4885ROCK1 761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.